A meta-analysis was conducted to assess the effect of omega-3 fatty acid supplementation (n-3 PUFAs) in lowering liver fat, liver enzyme (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels), and blood lipids (triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL)) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

Methods. MEDLINE/PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Science Citation Index (ISI Web of Science), Chinese Biomedical Literature Database (CBM), and Chinese National Knowledge Infrastructure (CNKI) were searched for relevant randomized controlled trials on the effects of n-3 polyunsaturated fatty acids (PUFAs) in patients with NAFLD from inception to May 2015. Ten studies were included in this meta-analysis.

Results. 577 cases of NAFLD/NASH in ten randomized controlled trials (RCTs) were included. The results of the meta-analysis showed that benefit changes in liver fat favored PUFAs treatment, and it was also beneficial for GGT, but it was not significant on ALT, AST, TC, and LDL.

Conclusions. In this meta-analysis, omega-3 PUFAs improved liver fat, GGT, TG, and HDL in patients with NAFLD/NASH. Therefore, n-3 PUFAs may be a new treatment option for NAFLD.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) involves the excess accumulation of hepatic fat in the absence of alcohol consumption and is defined by the presence of steatosis (characterized by lipid droplets) in more than 5% of hepatocytes [1]. The histological pattern of NAFLD can progress to nonalcoholic steatohepatitis (NASH). NAFLD is now one of the most common liver diseases worldwide. In Western countries and some regions of China, the prevalence of NASH and NAFLD is 1–5% and 15–39%, respectively [2]. One-third of NASH patients have advanced fibrosis and 20% develop cirrhosis [3]. The pathogenesis of NAFLD is multifactorial and includes excessive inappropriate dietary fat intake combined with peripheral insulin resistance, oxidative stress, and innate immunity [4]. It is frequently associated with obesity, type 2 diabetes (T2DM), dyslipidemia, metabolic syndrome, and cardiovascular disease [5–10].

Currently, several therapeutic approaches for NASH have been proposed. According to EASL-EASD-EASO guideline [11], patients without NASH or fibrosis should only receive counselling for healthy diet and physical activity and no pharmacotherapy for their liver condition and in overweight/obese NAFLD, a 7–10% weight loss is the target of most lifestyle interventions and results in improvement of liver enzymes and histology. No drug has currently been tested in phase III trials and is approved for NASH by regulatory agencies. The drugs studied in trials included insulin sensitizers (metformin [12], thiazolidinediones [13]), antioxidants (vitamin E [14], ursodeoxycholic acid), and...
cytoprotective and lipid lowering agents (n-3 polyunsaturated fatty acids). However, no specific therapy can be firmly recommended and any drug treatment would be off-label [15–17]. NASH patients with liver failure and/or HCC are candidates for liver transplantation [11].

NAFLD is considered to be associated with an excess of n-6 and a deficiency of n-3 polyunsaturated fatty acids (PUFAs) in the diet [18, 19]. Studies have indicated a lower PUFA content and a higher n-6/n-3 ratio in NAFLD patients [20, 21]. N-3 PUFAs are negative regulators of hepatic lipogenesis and the inflammatory response in mice [22, 23] and have a beneficial impact on hypertension, hyperlipidemia, endothelial dysfunction, and cardiovascular disease [24]. In the present study, we aimed to assess the effect of n-3 PUFAs supplementation in lowering liver fat, liver enzyme (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels), and blood lipids (TC, TG, HDL, and LDL) in patients with NAFLD.

2. Materials and Methods

2.1. Search Strategy. We searched MEDLINE/PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Science Citation Index (ISI Web of Science), Chinese Biomedical Literature Database (CBM), and Chinese National Knowledge Infrastructure (CNKI) from inception to May 2015 with no language restriction [25, 26]. The search terms included were as follows: (NASH or NAFLD or nonalcoholic steatohepatitis or nonalcoholic fatty liver disease or fatty liver or steatosis) and (n-3 PUFAs or omega-3 fatty acid or fish oil or n-3 polyunsaturated fatty acid or eicosapentaenoic acid or EPA or docosahexaenoic acid or DHA) and (Fatty Liver [MeSH] AND (n-3 polyunsaturated fatty acid) [MeSH]). We also searched the reference lists of each selected study by hand.

2.2. Inclusion and Exclusion Criteria. Articles were suitable if the following criteria were satisfied: (i) study design: RCT with the therapy of omega-3 fatty acid, and (ii) study population: patients with NAFLD identified according to the criteria as follows: (1) ultrasonography demonstrating fatty liver and (2) having no secondary hepatic fat accumulation such as significant alcohol consumption, use of steatogenic medication, or hereditary disorders. Studies were excluded for the following reasons: (i) trials that did not provide original data from which sensitivity or specificity could be calculated accurately; (ii) abstracts, letters, leading articles, animal experiments, expert opinion, book sections, case reports, and trials that lacked a control group; and (iii) other causes of hepatic steatosis or steatofibrosis, such as viral hepatitis, autoimmune hepatitis, liver decompensation, or malignancy.

2.3. Data Extraction. The search was conducted by two researchers (Wenxia Lu and Jianrong Wang) who read the titles and abstracts of studies independently and eliminated those which did not meet the inclusion criteria. The full texts of articles potentially meeting the inclusion criteria were cross-checked. Included data were extracted by two authors, respectively. The content of the data extracted was decided by discussion before data extraction. In order to avoid subjective bias, the author name, journal name, year, and country were hidden during data extraction. The following data were extracted by two researchers independently: (1) name of the first author, number of patients, year of publication, duration of treatment, daily dose of oral therapy, symptoms, and adverse events; (2) liver biochemistry (plasma ALT, AST, and GGT levels) and blood lipid (TG, TC, HDL, and LDL); (3) liver fatness quantified by needle biopsy and histological assessment, ultrasonography, or inferred by proton magnetic resonance spectroscopy (MRS).

2.4. Methodological Quality. The included RCTs were scored with the Jadad composite scale as follows.

Criteria Used to Grade the Quality of RCTs: The Jadad Scores. Each study was given one point for each “yes” and 0 points for each “no” in response to each of the following questions:

(1) Was the study described as randomized using the words “randomly,” “random,” or “randomization”?

(a) An additional point was given if the method of randomization was described and was appropriate (e.g., table of random numbers, computer generated).

(b) A point was deducted if the method of randomization was inappropriate (e.g., patients allocated alternately, by birth date, or by hospital number).

(2) Was the study described as “double blind”?

(a) A point was given if the method of blinding was described and it was appropriate (e.g., identical placebo).

(b) An additional point was deducted if the method of blinding was inappropriate (e.g., comparing placebo tablet with injection).

(3) Was there a description of the patients who withdrew or dropped out?

The maximum number of points was 5.

This is a five-point quality scale, with low-quality studies having a score of ≤2 and high-quality studies a score of ≥3. Methodological quality was independently assessed by the two authors of this study. Each study was given an overall score based on the criteria described above, which was then used to rank the studies. Any disagreement was resolved by consensus.

2.5. Data Synthesis. Analyses were conducted using RevMan 5.3. The odds ratio (OR) was presented with its 95% confidence interval (95% CI) only for liver fatness improvement event. Other curative effect evaluation indices were continuous variables, and the random effects model was used to
3. Results

3.1. Study Selection and Characteristics of the Studies Included. From 408 studies, we finally selected ten RCTs (Figure 1). Data on 577 individuals who participated in the RCTs were analyzed. Table 1 shows specific information on study design, sample size, intervention, control method, treatment dose, and duration of treatment. All studies were published as full-text articles. Eight studies used placebo as a control and two studies used no placebo or no treatment as a control. The median duration of treatment with omega-3 fatty acids was 12 months (range: 2 months to 18 months). The median dose of PUFAs was 2.85 g/day (range: 0.83–9 g/day) and there were no reports of adverse effects of omega-3 PUFA supplementation in the study reviewed.

Measurement methods used to quantify change in liver fatness included ultrasound (five studies), magnetic resonance spectroscopy (three studies), and liver biopsy (four studies). For the purpose of data pooling and analysis, the “high dose” group was selected as the treatment group for analysis in the study by Chen et al. [35] and Scorletti et al. [28].

3.2. Quality Evaluation of the Studies Included. Methodological quality scores ranged from 3 to 5 (Table 2). Eight of the ten randomized studies adequately described the way in which they were randomized. All studies used a double-blinded method, and seven provided specific descriptions of the blinding used. Eight studies described withdrawals and lost cases. Overall, the Jadad scores of all the RCTs were ≥3 points and were thus considered high-quality research.

3.3. Meta-Analysis

3.3.1. Effect of Omega-3 Fatty Acid Therapy on Liver Fat. Five studies demonstrated fatty liver with ultrasonography. Significant heterogeneity among studies was observed ($\chi^2 = 8.12, P = 0.09, I^2 = 51\%$), with a random effect model. There was a significant pooled OR for the efficacy of PUFA therapy on liver fat (OR = 3.60, 95% CI: 1.31 to 9.89, $P = 0.01$) (Figure 2).

3.3.2. Effect of Omega-3 Fatty Acid Therapy on Liver Function

ALT. Eight studies provided sufficient data to enable the calculation of MD and 95% CI for ALT. There was significant heterogeneity between the studies on the effects of PUFA supplementation on ALT ($\chi^2 = 17.18, P = 0.02, I^2 = 59\%$), with the random effects model, and the pooled MD for ALT showed a trend toward PUFA therapy versus control on ALT but did not reach statistical significance (MD = −4.97, 95% CI: −11.14 to 1.20, $P = 0.11$) (Figure 3).

AST. Seven studies assessed the effect of n-3 PUFAs on the level of serum AST. Significant heterogeneity was found to

**Figure 1:** Flow diagram of the studies included in the meta-analysis.
### Table 1: Baseline characteristics of the included studies.

| Authors, year [ref.] | Total | Population | Mean BMI category | Dose n-3/day | Duration | Control | Component n-3/1000mg capsule | Diagosis |
|----------------------|-------|------------|-------------------|--------------|----------|---------|-------------------------------|----------|
| Argo et al., 2015 [27] | 34    | NASH      | Obese            | 3000 mg      | 12 months| Placebo | 35% EPA + 250% DHA + 10% other n-3s | Liver biopsy + haematocochimical |
| Scorletti et al., 2014 [28] | 103   | NAFLD     | Obese            | 4000 mg      | 15–18 months | Placebo | 46% EPA + 38% DHA | Liver biopsy or imaging evidence or features of MetS |
| Sanyal et al., 2014 [29] | 119   | NASH/NAFLD| Obese            | 2700 mg      | 12 months | Placebo | Highly purified EPA ethyl ester | Liver biopsy + haematocochimical |
| Sofi et al., 2010 [30] | 11    | NAFLD     | Obese            | 830 mg       | 12 months | Placebo | 56.6% EPA + 28.9% DHA | Liver biopsy + haematocochimical |
| Dasarathy et al., 2015 [31] | 37    | NASH with diabetes | Obese | 3600 mg      | 12 months | Without treatment | 60% EPA + 40% DHA | Liver biopsy + haematocochimical |
| Zhu et al., 2008 [2] | 134   | NAFLD     | Obese            | 2000 mg      | 24 weeks | Placebo | Seal oils | Liver biopsy + haematocochimical |
| Spadaro et al., 2008 [32] | 36    | NAFLD     | Obese            | 2000 mg      | 6 months | Without treatment | Not mentioned | Liver biopsy + haematocochimical |
| Capanni et al., 2006 [33] | 56    | NAFLD     | Obese            | 1000 mg      | 12 months | Placebo | 37.5% EPA + 62.5% DHA | Liver biopsy + haematocochimical |
| Vega et al., 2008 [34] | 16    | Subset of DHS cohort | Obese | 9000 mg      | 8 wk | Placebo | 51.4% C20:5, 23.9% C22:6 | Elevated LFTs and TGs |
| Chen et al. 2008 [35] | 46    | NAFLD     | Not specified    | 5000 mg      | 24 wk    | Placebo | Harp seal oil capsules (not specified) | Elevated LFTs and TGs |
Table 2: Jadad quality scores of the trials included in the meta-analysis.

| Study year            | Randomization method | Double blinding | Withdrawals/dropouts | Total |
|-----------------------|----------------------|-----------------|----------------------|-------|
| Argo et al., 2015     | 2                    | 2               | 1                    | 5     |
| Scorletti et al., 2014| 2                    | 1               | 0                    | 3     |
| Sanyal et al., 2014   | 2                    | 2               | 1                    | 5     |
| Sofi et al., 2010     | 2                    | 2               | 1                    | 5     |
| Dasarathy et al., 2015| 1                    | 2               | 1                    | 4     |
| Zhu et al., 2008      | 2                    | 1               | 0                    | 3     |
| Spadaro et al., 2008  | 2                    | 2               | 1                    | 5     |
| Capanni et al., 2006  | 2                    | 2               | 1                    | 5     |
| Vega et al., 2008     | 2                    | 2               | 1                    | 5     |
| Chen et al., 2008     | 1                    | 1               | 1                    | 3     |

Experimental Control

| Study or subgroup | Experimental | Control | Weight | Odds ratio |
|-------------------|--------------|---------|--------|------------|
|                   | Events Total| Events Total| M-H, random, 95% CI | M-H, random, 95% CI |
| Capanni et al., 2006 | 27 42 0 14 | 9.6% 51.45 [2.87, 923.11] |
| Chen et al., 2008  | 11 15 6 16 | 21.9% 4.58 [0.99, 21.12] |
| Sofi et al., 2010  | 3 6 0 5 | 7.9% 11.00 [0.43, 284.30] |
| Spadaro et al., 2008 | 9 18 5 18 | 24.0% 2.60 [0.65, 10.38] |
| Zhu et al., 2008   | 35 66 29 68 | 36.6% 1.52 [0.77, 3.00] |
| Total (95% CI)     | 147 121 | 100.0% 3.60 [1.31, 9.89] |

Total events 85 40

Heterogeneity: $\chi^2 = 0.60; \chi^2 = 8.12, df = 4 (P = 0.09); I^2 = 51%
Test for overall effect: $Z = 2.49 (P = 0.01)$

Figure 2: Effects of n-3 PUFAs versus control in liver fat in patients with NAFLD.

3.3.3. Effect of Omega-3 Fatty Acid Therapy on Blood Lipids

Triglyceride. Nine studies provided sufficient data on triglyceride, and there was significant heterogeneity between the studies on the effect of PUFA supplementation on triglyceride ($\chi^2 = 29.17, P = 0.0003, I^2 = 73$%). With the random effects

exist between the studies on the effects of PUFA supplemen-
tation on AST ($\chi^2 = 38.51, P < 0.00001, I^2 = 84$%). With
the random effects model, it was not significant (MD = −2.01, 95% CI: −8.72 to 4.70, P = 0.58) (Figure 4).
model, there was statistical significance between the studies (MD = −35.55, 95% CI: −53.90 to 17.19, P = 0.0001) (Figure 6).

Total Cholesterol. Seven studies provided sufficient data on total cholesterol, and significant heterogeneity was found to exist between the studies on the effect of PUFA supplementation on total cholesterol (χ² = 10.53, P = 0.10, I² = 43%). Using the random effects model, it did not reach statistical significance (MD = −10.53, 95% CI: −10.4 to 3.09, P = 0.08) (Figure 7).

HDL. Seven studies reported the effect of n-3 PUFAs on serum HDL reduction, and there was significant heterogeneity between the studies on the effect of PUFA supplementation on HDL (χ² = 30.09, P < 0.0001, I² = 80%). Using the random effects model, there was significant pooled MD favoring PUFA therapy versus control on HDL (MD = 5.51, 95% CI: 0.03 to 11, P = 0.05) (Figure 8).

LDL. Six studies provided sufficient data on total LDL, and low heterogeneity was found to exist between the studies on
the effect of PUFA supplementation on LDL ($\chi^2 = 1.28$, $P = 0.34$, $I^2 = 12\%$). With the fixed effects model, it did not reach statistical significance (MD = 1.28, 95% CI: −0.34 to 6.63, $P = 0.64$) (Figure 9).

3.4. Publication Bias. Figure 10 shows the funnel plots of the meta-analysis. The funnel plot analyses of AST, ALT, GGT, TC, TG, HDL, and LDL showed slight asymmetry, indicating that there was a certain publication bias.

### 4. Discussion

Due to improvements in living standards, changes in lifestyle and the prevalence of obesity, diabetes, and the metabolic syndrome, the annual increase in the incidence of NAFLD has become a global public health problem. Currently, NASH is rapidly increasing as a cause of end-stage liver disease and hepatic carcinoma. At present, there is no registered drug for the treatment of NAFLD, and there is a need to
Figure 10: Funnel plots for the meta-analysis.
improve therapeutics for this condition. The n-3 PUFAs have been shown to reduce inflammation, enhance insulin sensitivity, and improve hypertriglyceridemia [36]. A meta-analysis indicated that n-3 PUFAs supplements significantly decreased the amount of liver fat observed on ultrasound [37]. n-3 PUFAs have also been used to effectively improve dyslipidemia [33, 36, 38]. The present meta-analysis aimed to assess the effect of n-3 PUFAs on liver fat (demonstrated with ultrasonography), liver enzyme levels (ALT, AST, and GGT) and blood lipid levels (TG, TC, HDL, and LDL) in patients with NAFLD and NASH. The results indicated that n-3 PUFAs can optimize liver fat, GGT, TG, and HDL levels in patients with NAFLD, suggesting the therapeutic potential of n-3 PUFAs in this liver disease.

Our results were in accordance with a recent review by Parker et al. [37], which provide a meta-analysis of liver fat, ALT, and AST data from seven RCTs at that time. It showed a benefit on liver fatness and found no significant benefit on ALT and AST levels. The current data also suggest that GGT is affected by n-3 PUFAs. Furthermore, it is well acknowledged that there is high intrapatient variability in liver tests which may reduce the ability to detect significant changes in these parameters.

Although six studies were identified that examined the effect of dietary omega-3 PUFAs supplementation on liver fat by ultrasonography, one study could not be included in liver fat analyses because of insufficient data. Two, three, six, three, four, three, and two studies had insufficient data for inclusion in ALT analyses, AST analyses, GGT analyses, TC analyses, TG analyses, HDL analyses, and LDL analyses, respectively.

N-3 PUFAs supplements to decrease plasma TG may be associated with glycemic control, as shown in a study of NASH patients with diabetes [31]. It has been demonstrated that n-3 PUFAs activate the peroxisome proliferator-activated receptor (PPAR) alpha, which in turn stimulates fatty acid oxidation [39], and PPAR gamma increases insulin sensitivity [40], inhibits hepatic lipogenesis, and reduces hepatic reactive oxygen species [41]. Besides, patients with NAFLD have been shown to have a greater deficiency of n-3 PUFAs in the diet than healthy controls [42, 43], and a higher n-6/n-3 ratio in NAFLD patients increased lipogenesis leading to steatosis [44].

There were several limitations in our study. First, the number of studies included in this analysis was small. Second, the diagnosis of NAFLD/NASH in the present study was confirmed by liver biopsy, ultrasonography, or MRI. Although ultrasonography is reasonably accurate, it cannot identify fatty infiltration of the liver below a threshold of 30% [37]. Unfortunately, only 4 studies provided posttreatment histology results. Third, a pathogenesis of NAFLD should be established and improved in the near future, to facilitate research into the molecular markers, diagnosis of NAFLD, and target therapies [45–47].

In summary, the results of our meta-analysis support the beneficial effect of n-3 PUFAs in optimizing liver fat, liver enzyme levels (GGT), and blood lipid levels (TG, HDL) in patients with NAFLD and we guess n-3 PUFAs may slow down the progress of NAFLD. More studies with a rigorous design, large sample size, and multiregional cooperation are necessary to examine the therapeutic effect of n-3 PUFA supplementation.

**Competing Interests**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Wenxia Lu, Sainan Li, and Jingjing Li contributed equally to this work and should be considered co-first authors.

**References**

[1] P. Angulo, “Nonalcoholic fatty liver disease,” *The New England Journal of Medicine*, vol. 346, no. 16, pp. 1221–1231, 2002.

[2] F.-S. Zhu, S. Liu, X.-M. Chen, Z.-G. Huang, and D.-W. Zhang, “Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia,” *World Journal of Gastroenterology*, vol. 14, no. 41, pp. 6395–6400, 2008.

[3] M. R. Pagadala and A. J. McCullough, “The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis,” *Clinics in Liver Disease*, vol. 16, no. 3, pp. 487–504, 2012.

[4] J. Lizardi-Cervera and D. Aguilar-Zapata, “Nonalcoholic fatty liver disease and its association with cardiovascular disease,” *Annuals of Hepatology*, vol. 8, no. 1, pp. S40–S43, 2009.

[5] G. Targher, C. P. Day, and E. Bonora, “Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease,” *The New England Journal of Medicine*, vol. 363, no. 14, pp. 1341–1350, 2010.

[6] L. S. Bhatia, N. P. Curzen, P. C. Calder, and C. D. Byrne, “Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?” *European Heart Journal*, vol. 33, no. 10, pp. 1190–1200, 2012.

[7] G. Targher and C. D. Byrne, “Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications,” *Journal of Clinical Endocrinology and Metabolism*, vol. 98, no. 2, pp. 483–495, 2013.

[8] C. K. Argo, P. G. Northup, A. M. S. Al-Osaimi, and S. H. Caldwell, “Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis,” *Journal of Hepatology*, vol. 51, no. 2, pp. 371–379, 2009.

[9] N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology,” *Gastroenterology*, vol. 142, no. 7, pp. 1592–1609, 2012.

[10] A. P. Levene and R. D. Goldin, “The epidemiology, pathogenesis and histopathology of fatty liver disease,” *Histopathology*, vol. 61, no. 2, pp. 141–152, 2012.

[11] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO), “EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease,” *Journal of Hepatology*, vol. 64, no. 6, pp. 1388–1402, 2016.
[12] M. Tiikkainen, A.-M. Häkkinen, E. Korsheninnikova, T. Nyman, S. Mákimattila, and H. Yki-Järvinen, "Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes," *Diabetes*, vol. 55, no. 8, pp. 2169–2176, 2004.

[13] A. J. Sanay, N. Chalasani, K. V. Kowdley et al., "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis," *The New England Journal of Medicine*, vol. 362, no. 18, pp. 1675–1685, 2010.

[14] J. H. Hoofnagle, M. L. Van Natta, D. E. Kleiner et al., "Vitamin E, or placebo for nonalcoholic steatohepatitis—a case for personalised treatment based on pathogenic targets," *Alimentary Pharmacology and Therapeutics*, vol. 38, no. 2, pp. 134–143, 2013.

[15] Z. M. Younossi, M. J. Reyes, A. Mishra, R. Mehta, and L. Henry, "Systematic review with meta-analysis: non-alcoholic steatohepatitis—a case for personalised treatment based on pathogenic targets," *Alimentary Pharmacology and Therapeutics*, vol. 39, no. 1, pp. 3–14, 2014.

[16] N. Mazzella, L. M. Ricciardi, A. Mazzotti, and G. Marchesini, "The role of medications for the management of patients with NAFLD," *Clinical in Liver Disease*, vol. 18, no. 1, pp. 73–89, 2014.

[17] V. Ratziu, Z. Goodman, and A. Sanay, "Current efforts and trends in the treatment of NASH," *Journal of Hepatology*, vol. 62, no. 1, pp. S65–S75, 2015.

[18] J. Araya, R. Rodrigo, L. A. Videla et al., "Increase in long-chain polysaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease," *Clinical Science*, vol. 106, no. 6, pp. 635–643, 2004.

[19] K. Promrat, D. E. Kleiner, H. M. Niemeier et al., "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis," *Hepatology*, vol. 51, no. 1, pp. 121–129, 2010.

[20] M. Lazo and J. M. Clark, "The epidemiology of nonalcoholic fatty liver disease: a global perspective," *Seminars in Liver Disease*, vol. 28, no. 4, pp. 339–350, 2008.

[21] A. P. Simopoulos, "Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet," *World Review of Nutrition and Dietetics*, vol. 102, pp. 10–21, 2011.

[22] I. P. J. Alwayn, K. Gura, V. Nosé et al., "Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease," *Pediatric Research*, vol. 57, no. 3, pp. 445–452, 2005.

[23] M.-T. Wu, H.-N. Chou, and C.-J. Huang, "Dietary fucoxanthin increases metabolic rate and upregulated mRNA expressions of the PGC-1alpha network, mitochondrial biogenesis and fusion genes in white adipose tissues of mice," *Marine Drugs*, vol. 12, no. 2, pp. 964–982, 2014.

[24] D. Kromhout, S. Yasuda, J. M. Geleijns, and H. Shimokawa, "Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?" *European Heart Journal*, vol. 33, no. 4, pp. 436–443, 2012.

[25] H. Zhang, J. Yang, R. Zhu et al., "Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis," *Drug Design, Development and Therapy*, vol. 9, pp. 567–574, 2015.

[26] Y. Zhang, S. Li, L. He et al., "Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis," *Drug Design, Development and Therapy*, vol. 9, pp. 2757–2766, 2015.

[27] C. K. Argo, J. T. Patrie, C. Lackner et al., "Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial," *Journal of Hepatology*, vol. 62, no. 1, pp. 190–197, 2015.

[28] E. Scorletti, L. Bhatia, K. G. McCormick et al., "Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME study," *Hepatology*, vol. 60, no. 4, pp. 1211–1221, 2014.

[29] A. J. Sanay, M. F. Abdelmalek, A. Suzuki, O. W. Cummings, and M. Choikier, "No significant effects of ethyl-eicosapentaenoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial," *Gastroenterology*, vol. 147, no. 2, pp. 377–384.e1, 2014.

[30] F. Sofi, I. Giangrandi, F. Cesari et al., "Effects of a 1-year dietary intervention with n-3 polysaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study," *International Journal of Food Sciences and Nutrition*, vol. 61, no. 8, pp. 792–802, 2010.

[31] S. Dasarathy, J. Dasarathy, A. Khiyami et al., "Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis," *Journal of Clinical Gastroenterology*, vol. 49, no. 2, pp. 137–144, 2015.

[32] L. Spadaro, O. Magliocco, D. Spampinato et al., "Effects of n-3 polysaturated fatty acids in subjects with nonalcoholic fatty liver disease," *Digestive and Liver Disease*, vol. 40, no. 3, pp. 194–199, 2008.

[33] M. Capanni, F. Calella, M. R. Biagini et al., "Prolonged n-3 polysaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study," *Alimentary Pharmacology and Therapeutics*, vol. 23, no. 8, pp. 1143–1151, 2006.

[34] G. L. Vega, M. Chandalia, L. S. Szczepaniak, and S. M. Grundy, "Effects of N-3 fatty acids on hepatic triglyceride content in humans," *Journal of Investigative Medicine*, vol. 56, no. 5, pp. 780–785, 2008.

[35] R. Chen, Q. Guo, W.-J. Zhu, Q. Xie, H. Wang, and W. Cai, "Therapeutic efficacy of α-3 polysaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease," *World Chinese Journal of Digestology*, vol. 16, no. 18, pp. 2002–2006, 2008.

[36] I. P. J. Alwayn, C. Andersson, B. Zauscher, K. Gura, V. Nosé, and M. Puder, "Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor," *Transplantation*, vol. 79, no. 5, pp. 606–608, 2005.

[37] H. M. Parker, N. A. Johnson, C. A. Burdon, J. S. Cohn, H. T. O’Connor, and J. George, "Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis," *Journal of Hepatology*, vol. 56, no. 4, pp. 944–951, 2012.

[38] N. Tanaka, K. Sano, A. Horiuichi, E. Tanaka, K. Kiyosawa, and T. Aoyama, "Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis," *Journal of Clinical Gastroenterology*, vol. 42, no. 4, pp. 413–418, 2008.

[39] J. Zúñiga, M. Cancino, F. Medina et al., "N-3 PUFA supplementation triggers PPAR-α activation and PPAR-α/NFκB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury," *PLoS ONE*, vol. 6, no. 12, Article ID e28502, 2011.

[40] Y. B. Lombardo and A. G. Chicco, "Effects of dietary polysaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review," *Journal of Nutritional Biochemistry*, vol. 17, no. 1, pp. 1–13, 2006.
hepatocyte-specific Pten-deficient mice," *Journal of Hepatology*, vol. 50, no. 3, pp. 562–571, 2009.

[42] H. Cortez-Pinto, L. Jesus, H. Barros, C. Lopes, M. C. Moura, and M. E. Camilo, "How different is the dietary pattern in non-alcoholic steatohepatitis patients?" *Clinical Nutrition*, vol. 25, no. 5, pp. 816–823, 2006.

[43] K. Toshimitsu, B. Matsuura, I. Ohkubo et al., “Dietary habits and nutrient intake in non-alcoholic steatohepatitis," *Clinical Nutrition*, vol. 25, no. 5, pp. 816–823, 2006.

[44] A. M. Zivkovic, J. B. German, and A. J. Sanyal, "Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease," *American Journal of Clinical Nutrition*, vol. 86, no. 2, pp. 285–300, 2007.

[45] P. Cheng, K. Chen, Y. Xia et al., “Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis," *Drug Design, Development and Therapy*, vol. 8, pp. 1277–1286, 2014.

[46] W. Dai, F. Wang, L. He et al., “Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor NFAT1," *Molecular Carcinogenesis*, vol. 54, no. 4, pp. 301–311, 2015.

[47] W. Dai, F. Wang, J. Lu et al., “By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice," *Oncotarget*, vol. 6, no. 15, pp. 13703–13717, 2015.